InsiderSignal.AI

InsiderSignal.ai

COLL - Collegium Pharmaceutical, Inc

Insider Sale by Dreyer Scott (EVP, Chief Commercial Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Dreyer Scott, serving as EVP, Chief Commercial Officer at Collegium Pharmaceutical, Inc (COLL), sold 49,976 shares at $40.41 per share, for a total transaction value of $2,019,437.00. Following this transaction, Dreyer Scott now holds 71,770 shares of COLL.

This sale represents a 41.00% decrease in Dreyer Scott's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, March 3, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, March 5, 2026, 2 days after the trade was made.

Collegium Pharmaceutical, Inc operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Dreyer Scott

Dreyer Scott

EVP, Chief Commercial Officer

Scott Dreyer is the Executive Vice President and Chief Commercial Officer at Collegium Pharmaceutical, Inc. (NASDAQ: COLL), a role he has held since July 2018 after joining the company in January 2018.[[1]](https://fintool.com/app/research/companies/COLL/people/scott-dreyer)[[4]](https://www.collegiumpharma.com/company/) With over 25 years of experience in biopharma commercial leadership, including sales, marketing, commercial operations, and strategy, Dreyer previously served as Senior Vice President of Marketing and Commercial Operations at The Medicines Company and Vice President and Chief Marketing Officer – U.S. at Biogen.[[1]](https://fintool.com/app/research/companies/COLL/people/scott-dreyer) He holds a B.S. in Biology from Messiah College and is approximately 53 years old.[[1]](https://fintool.com/app/research/companies/COLL/people/scott-dreyer) Dreyer has contributed to Collegium's strong performance, including record 2024 net product revenue of $631.4 million (up 11% year-over-year) and Adjusted EBITDA of $401.2 million.[[1]](https://fintool.com/app/research/companies/COLL/people/scott-dreyer) On December 8, 2025, he sold 17,600 shares under a pre-arranged 10b5-1 plan for approximately $847,855 while exercising options, retaining direct ownership of 103,613 shares; he is noted as a 10% owner.[[2]](https://www.investing.com/news/insider-trading-news/collegium-pharmaceutical-evp-dreyer-sells-847k-in-stock-93CH-4401861)[[3]](https://www.tradingview.com/news/tradingview:7e202dc6b16dd:0-collegium-pharmaceutical-evp-scott-dreyer-sells-shares/)

View full insider profile →

Trade Price

$40.41

Quantity

49,976

Total Value

$2,019,437.00

Shares Owned

71,770

Trade Date

Tuesday, March 3, 2026

3 days ago

SEC Filing Date

Thursday, March 5, 2026

Filed 2 days after trade

HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC

About Collegium Pharmaceutical, Inc

Company Overview

No company information available
View news mentioning COLL

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4524570

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime